Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases

被引：0
|
作者：
Ballard, Peter [1 ]
Yang, Pamela [2 ]
Cross, Darren [3 ]
Yates, James [3 ]
Finlay, M. Raymond V. [3 ]
Grist, Matthew [1 ]
Box, Matthew [1 ]
Johnstrom, Peter [4 ,5 ]
Varnas, Katerina [5 ]
Malmquist, Jonas [5 ]
Halldin, Christer [5 ]
Farde, Lars [4 ,5 ]
Thress, Kenneth [6 ]
机构：
[1] Astrazeneca, Macclesfield, Cheshire, England
[2] Astrazeneca, Asia & Emerging Markets, Shanghai, Peoples R China
[3] Astrazeneca, Cambridge, England
[4] Karolinska Inst, Astrazeneca Translat Sci Ctr, Stockholm, Sweden
[5] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[6] Astrazeneca, Waltham, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
T790M; EGFR-TKI; brain metastases;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI10.12
引用
收藏
页码：S300 / S300
页数：1
相关论文
共 50 条
  • [1] AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
    Ahn, M. J.
    Tsai, C. M.
    Yang, J. C. H.
    Shepherd, F. A.
    Satouchi, M.
    Kim, D. W.
    Bazhenova, L.
    Hirashima, T.
    Rukazenkov, Y.
    Cantarini, M.
    Mann, H.
    Ramalingam, S. S.
    Mitsudomi, T.
    Jaenne, P. A.
    Goss, G. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S625 - S626
  • [2] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    [J]. FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [3] High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Nanjo, Shigeki
    Ebi, Hiromichi
    Arai, Sachiko
    Takeuchi, Shinji
    Yamada, Tadaaki
    Mochizuki, Satsuki
    Okada, Yasunori
    Nakada, Mitsutoshi
    Murakami, Takashi
    Yano, Seiji
    [J]. ONCOTARGET, 2016, 7 (04) : 3847 - 3856
  • [4] Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC
    Planchard, David
    Kris, Mark
    Besse, Benjamin
    Hozak, Rebecca
    He, Shuang
    Gan, Frank
    Wolff, Katharina
    Chao, Bo
    Yu, Helena
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1071 - S1071
  • [5] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    Ballard, Peter
    Yates, James W. T.
    Yang, Zhenfan
    Kim, Dong-Wan
    Yang, James Chih-Hsin
    Cantarini, Mireille
    Pickup, Kathryn
    Jordan, Angela
    Hickey, Mike
    Grist, Matthew
    Box, Matthew
    Johnstrom, Peter
    Varnas, Katarina
    Malmquist, Jonas
    Thress, Kenneth S.
    Janne, Pasi A.
    Cross, Darren
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5130 - 5140
  • [6] The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613
    Remon, Jordi
    Menis, Jessica
    Hasan, Baktiar
    Peric, Aleksandra
    De Maio, Eleonora
    Novello, Silvia
    Reck, Martin
    Berghmans, Thierry
    Wasag, Bartosz
    Besse, Benjamin
    Dziadziuszko, Rafal
    [J]. CLINICAL LUNG CANCER, 2017, 18 (05) : 583 - 588
  • [7] Lentiviral Insertional Mutagenesis Helps to Uncover the Mechanisms of Resistance to AZD9291 and CO-1686 in EGFR-Mutant Lung Adenocarcinoma
    Pirazzoli, Valentina
    Spinozzi, Giulio
    Tenderini, Erika
    Benedicenti, Fabrizio
    Calabria, Andrea
    Montini, Eugenio
    [J]. MOLECULAR THERAPY, 2016, 24 : S83 - S83
  • [8] Diverse EGFR mutations explain AZD9291 resistance
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 438 - 438
  • [9] Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Mitsuya, Koichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakasu, Yoko
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
    Savastano, B.
    Della Corte, C. M.
    Papaccio, F.
    Giuseppe, V.
    Esposito, G.
    Fasano, M.
    Orditura, M.
    De Vita, F.
    Ciardiello, F.
    Morgillo, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345